Italia markets closed

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
38,35-0,20 (-0,52%)
Alla chiusura: 06:15PM BST

Basilea Pharmaceutica AG

Grenzacherstrasse 487
Basel 4058
Switzerland
41 61 606 11 11
https://www.basilea.com

Settore/i
Settore
Impiegati a tempo pieno154

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. David VeitchChief Exec. Officer1,11MN/D1965
Mr. Adesh KaulChief Financial OfficerN/DN/D1974
Dr. Gerrit Hauck Ph.D.Chief Technology OfficerN/DN/D1964
Dr. Laurenz Kellenberger Ph.D.Chief Scientific OfficerN/DN/D1967
Dr. Marc Engelhardt M.D.Chief Medical OfficerN/DN/D1964
Dr. Peer Nils SchroderHead of Corp. Communications & Investor RelationsN/DN/DN/D
Mr. Damian HellerGen. Counsel & Corp. Sec.N/DN/D1966
Ms. Ursula EberhardtHead of Global HRN/DN/D1962
Mr. Lutz WevelsiepHead of Regulatory AffairsN/DN/DN/D
Mr. Dietrich StüberHead of Internal ServicesN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Basilea Pharmaceutica AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.